Niclosamide  (Synonyms: BAY2353)

Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research^[1]. Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells^[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells^[2][3][5].

Niclosamide (0.6 nM-46 μM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells^[3].
Niclosamide (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells ^[4].
Niclosamide (10 μM) inhibits virus replication in Vero E6 cells.

Niclosamide (GMP) (up to 2 μM, 24 h) inhibites Zika virus infection in SNB-19 cells^[6].
Niclosamide (GMP) (1.5 μM，5 d) inhibites nuclear factor‐κB ligand (RANKL)-induced transdifferentiation of macrophages into osteoclast precursors, particularly in the early stage of osteoclastogenesis^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Niclosamide (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

327.12

C₁₃H₈Cl₂N₂O₄

50-65-7

O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95.  [Content Brief]

  [2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.  [Content Brief]

  [3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66.  [Content Brief]

  [4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9.  [Content Brief]

  [5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.  [Content Brief]

  [6]. Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22(10):1101-1107.  [Content Brief]

  [7]. Jiao Y, Chen C, Hu X, et al. Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis. FEBS Open Bio. 2020;10(8):1685-1697. doi:10.1002/2211-5463.12921  [Content Brief]